At least three Big Law firms are steering AstraZeneca’s proposed acquisition of Amolyt Pharma, a French clinical-stage biotechnology company, in a deal valued at up to $1.05 billion.
Freshfields Bruckhaus Deringer said it was counseling U.K.-based AstraZeneca, while Jones Day and Cooley said they were advising Amolyt Pharma, which is based in a suburb of Lyon, France, and its shareholders.
